Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com

Posted by Stacy Sanders on Dec 26th, 2024

StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX – Free Report) in a research note issued to investors on Tuesday. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Trading Up 1.1 %

Shares of Brooklyn ImmunoTherapeutics stock opened at $0.25 on Tuesday. Brooklyn ImmunoTherapeutics has a 1-year low of $0.17 and a 1-year high of $10.10. The firm’s 50-day moving average price is $0.65 and its two-hundred day moving average price is $1.29. The stock has a market capitalization of $14.71 million, a price-to-earnings ratio of -0.11 and a beta of 4.61.

About Brooklyn ImmunoTherapeutics

(Get Free Report)

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.